Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Centre Hospitalier Universitaire De Montpellier

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Philippe Pasero

Jérôme Moreaux

Guillaume Cartron

Caroline Bret

Angelos Constantinou

The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein &#x3b2;i represent the regression &#x3b2; coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=&#x2212;1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSv) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSor concluding that the patient will not respond to the treatment when the DNARS score is lower than the predetermined reference value DNARS. 

Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma

Growing community of inventors

Montpellier, France

Philippe Pasero